Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Inhaled RV568 in COPD
NCT01475292Phase 2Completed
- Sponsor
- RespiVert
- Start
- Nov 2011
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RV568 in chronic obstructive pulmonary disease (COPD), sponsored by RespiVert. Started Nov 2011; status: completed.
02
Drugs
RV568
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01475292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01475292.